NCT02008292View on ClinicalTrials.gov

Acetylcholine, Tobacco Smoking, Genes and Nicotinic Receptors

NACompletedINTERVENTIONAL
Enrollment

80

Participants

Timeline

Start Date

September 30, 2013

Primary Completion Date

December 31, 2021

Study Completion Date

December 31, 2021

Conditions
SmokingSchizophrenia
Interventions
DRUG

Physostigmine

All subjects will receive physostigmine to induce elevated ACh levels in the brain.

Trial Locations (3)

06519

Connecticut Mental Health Center, New Haven

Yale Magnetic Resonance Research Center, New Haven

Yale PET Center, New Haven

All Listed Sponsors
collaborator

National Institutes of Health (NIH)

NIH

collaborator

National Institute on Drug Abuse (NIDA)

NIH

lead

Yale University

OTHER

NCT02008292 - Acetylcholine, Tobacco Smoking, Genes and Nicotinic Receptors | Biotech Hunter | Biotech Hunter